Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES)
Peter K. H. Lau, Breon Feran, Lorey Smith, Arian Lasocki, Ramyar Molania, Kortnye Smith, Alison M. Weppler, Christopher Angel, Damien Kee, Prachi Bhave, Belinda Lee, Richard J. Young, Amir Iravani, Hanxian Aw Yeang, Ismael A. Vergara, David L. Kok, Kate Drummond, Paul J. Neeson, Karen E. Sheppard, Anthony T. Papenfuss, Benjamin Solomon, Shahneen Sandhu, Grant A. McArthur (2021). Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES). , 9(10), DOI: https://doi.org/10.1136/jitc-2021-002995.
